Bambusa Therapeutics, Inc. is listed on the Nasdaq Global Select Market under the ticker symbol "BBTX."
We became a publicly traded company on October 29, 2026, and our common stock began trading on the Nasdaq Global Select Market on October 30, 2026.
Bambusa Therapeutics is headquartered in Boston, Massachusetts, at 22 Boston Wharf Road, Floor 7, Boston, MA 02210.
Bambusa Therapeutics is incorporated in the State of Delaware.
Our fiscal year ends on December 31.
Our transfer agent and registrar is Fidelity Stock Transfer Solutions LLC.
Our independent registered public accounting firm is PricewaterhouseCoopers LLP (PwC).
Our corporate legal counsel is Wilson Sonsini Goodrich & Rosati, P.C.
We have not declared or paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.
Shares of Bambusa Therapeutics common stock may be purchased through a licensed brokerage firm.
Our SEC filings are available through the SEC's website at www.sec.gov and in the SEC Filings section of our Investor Relations website.
Investors can subscribe to company news and updates through the Email Alerts section of our Investor Relations website.
For investor-related inquiries, please contact us at investors@bambusatx.com.